Taxa Technologies leverages synthetic biology and microbiome engineering to develop consumer-facing personal care ingredients. The company uses subspecies-level ‘omics analysis and gene-editing tools to steer site-specific microbiomes at the level of individual metabolic pathways. Taxa emphasizes a consumer-first approach, designing ingredient profiles that are more effective and less toxic—often two to three fermented ingredients rather than harsh synthetic chemicals. Leadership says the firm is technology-agnostic and will pivot if a better technical solution emerges. The company plans to begin commercialization in Japan (where a co-founder is based) and then expand to the U.S. and Europe. Taxa recently completed an oversubscribed $2.5M pre-seed round to hire a multidisciplinary team and advance product development.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2024